Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you believe this 18 months ago was trading around $230+? Now is $57 and going down.
You missing the fact that the tinfoil is fake... will be gone soon.
Must have also missed all analysts downgrading it....
And that SP has dropped by about 50% during last month...
Quoting AACR the only one to publish Adam Feuersteins hit piece from May 10th. and afterwards withdraw it. AACR who continously are granting NVCR awards.
Personally I love the history of the NVCR board on Ihub especially in comparison to NWBO. A stroll down menory lane from last year.
I also love the recent development. That NVCR announced a PR about their LUNAR "device" before a weekend, springing the SP to $118. SEC filing shows that almost all of management used that timeframe to sell a lot of shares before another SEC filing after the weekend showed NVCR only had around 3.400 patients GLOBALLY and can not attract more.
SP dropped BAAAM.
But no worries. Afterwards a lot in the management secured shares at $0 and a lot sold again late February and early March.
BAAAAM.
$1M just directly into the pocket.
And now JP Morgan has downgraded NVCR to $50. The SP has already dropped from $118 to $57 and waddayaknow, completely without spoofing and counterfitting involved. STILL their SP fell more than NWBO.
Speaks volumes where NVCR are going. Their "science" is being eradicated by personal vaccines actually helping patients to get better, not stay status quo for a while a the price of $21.000 a month.
All the while NO ONE from the NWBO management have sold one share. Not above $2 either. For years.
But obviously Jerry Jasinowski felt like adding for $600.000 at $0.85 in December.
Also,
Tumor treating fields induce immune modulation in non-small cell lung cancer https://www.abstractsonline.com/pp8/#!/10828/presentation/3202
Investigation of sponge property for enhanced concurrent tumor treating fields and radiotherapy for glioblastoma https://www.abstractsonline.com/pp8/#!/10828/presentation/5415
TTFields-prolonged the PFS of epithelioid glioblastoma patient: a case report https://www.abstractsonline.com/pp8/#!/10828/presentation/1567
TTFields combined with temozolomide and immunotherapy show long-term PFS on a GBM patients with multiple negative prognostic factors https://www.abstractsonline.com/pp8/#!/10828/presentation/3145
Safety and efficacy of Tumor Treating Fields (TTFields) combined with bevacizumab and systemic chemotherapy in recurrent GBM https://www.abstractsonline.com/pp8/#!/10828/presentation/10455
The impact of tumor-treating fields on cancer stem-like cells isolated from the sub-ventricular zone of glioblastoma patients https://www.abstractsonline.com/pp8/#!/10828/presentation/2753
AACR abstracts (the event is next month).
TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma https://www.abstractsonline.com/pp8/#!/10828/presentation/10498
Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin or paclitaxel for treatment of cervical cancer https://www.abstractsonline.com/pp8/#!/10828/presentation/2709
Tumor treating fields combined with the PULSAR paradigm for radiotherapy and an immune checkpoint inhibitor enhances antitumor efficacy in vivo https://www.abstractsonline.com/pp8/#!/10828/presentation/4735
Establishing the cytotoxic benefit of Tumor Treating Fields on radiation sensitive and acquired radiation resistant glioblastoma patient derived xenograft pairs https://www.abstractsonline.com/pp8/#!/10828/presentation/1473
Theoretical basis and formula for tumor-treating fields dose-response curves https://www.abstractsonline.com/pp8/#!/10828/presentation/1498
In vitro and in vivo investigation of tumor treating fields for treatment of spinal metastasis https://www.abstractsonline.com/pp8/#!/10828/presentation/2371
Sensitizing cancer cell to doxorubicin by tumor treating fields (TTFields)-induced, elevated membrane permeability https://www.abstractsonline.com/pp8/#!/10828/presentation/9326
Tumor treating fields exposure causes an imbalance of reactive oxygen homeostasis likely through the cytosolic function of the fanconi's anemia genes https://www.abstractsonline.com/pp8/#!/10828/presentation/5953
Treatment of gastric cancer cells with tumor treating fields (TTFields) and concomitant FOLFOX https://www.abstractsonline.com/pp8/#!/10828/presentation/2737
Evaluation of tumor treating fields (TTFields) effects at 200 kHz on a glioblastoma, an anaplastic ependymoma and an oligodendroglioma sample in a patient-derived ex vivo organoid model https://www.abstractsonline.com/pp8/#!/10828/presentation/2328
PI3K inhibition sensitize cancer cells to tumor treating fields (TTFields) https://www.abstractsonline.com/pp8/#!/10828/presentation/1615
Pan cancer transcriptomic response to tumor treating fields (TTFields) https://www.abstractsonline.com/pp8/#!/10828/presentation/1770
Association of Tumor Treating Fields (TTFields) with survival in newly diagnosed glioblastoma: A systematic review and meta-analysis https://www.abstractsonline.com/pp8/#!/10828/presentation/1556
Inhibition of AURKA destabilizes glioblastoma primary cilia and sensitizes cells to tumor treating fields (TTFields) in vitro and ex vivo https://www.abstractsonline.com/pp8/#!/10828/presentation/7221
Enhancing treatment efficacy of glioblastoma cell lines by adding tumor treating fields (TTFields) to temozolomide and lomustine https://www.abstractsonline.com/pp8/#!/10828/presentation/1826
Tumor treating fields (TTFields) concomitant with PARP inhibitors or carboplatin for treatment of ovarian cancer cell lines https://www.abstractsonline.com/pp8/#!/10828/presentation/1832
CLIC1 and CLIC4 ion channels as bioelectric targets for tumor treating fields in pediatric high-grade glioma https://www.abstractsonline.com/pp8/#!/10828/presentation/5522
Patients with glioblastoma (GBM) treated with tumor treating fields (TTFields) therapy: post-marketing safety data over the last decade https://www.abstractsonline.com/pp8/#!/10828/presentation/1564
TTFields reduce sensitivity in glioblastoma is associated with the functional expression of the chloride intracellular channel 1 and with voltage dependent sodium channel https://www.abstractsonline.com/pp8/#!/10828/presentation/2043
Simply put, no.
Hello everyone, I got back into $NVCR this morning, 5K starter shares, will add on weakness! GLTA
Novocure aims to plough a new field https://www.evaluate.com/vantage/articles/interviews/novocure-aims-plough-new-field
Why HyGro is so worried??. He spends lots of time on NWBO MB. hummm
Ignore it.
Today News: After a review of Novocure’s future needs, Ely Benaim, M.D., Chief Medical Officer, will step down from his role and leave the company.
Very Telling Where this is headed....
Very Telling. The 6 officers combined sold over 260,000 shares all about $100/Share..
That's over $26M worth of shares they dumped!!
Did anyone else read this telling post
It's strange there's no activity on this board. Something doesn't seem right.
How's it going?
The Big Short - SCAM alert- The heat cap is at best as good as CHEMO!! IMO
Anyone else think this thing is a high level scam. I don’t think they have one 5 yr survivor
Did the CEO dump virtually his entire position? WTF is that about
You got that Absolutely right norisknorewards..
NVCR ends is closer than what that dude wishes not to be...
The device is no better than CHEMO!!
Easiest short he said
FDA Cleared CHEMO as well just incase... And that has miserably failed///
There is absolutely NO CURE in NoVoCure!!
Best Short EVER IMO
This below statement from their PR confirms that fact!!
".....which has the Potential to meaningfully extend patient survival beyond what was previously possible.,& that says it all. |the Potential .. to extend ..Survival" ... Its all that she wrote~~~~
Could be this am conference today?
Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.
“We are pleased with the positive readout of the LUNAR study. Prior to LUNAR, the last phase 3 trial to lead to significant improvement in overall survival in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease,” said William Doyle, Novocure’s Executive Chairman. “We are also pleased by the profound performance of the TTFields together with immunotherapy, which has the potential to meaningfully extend patient survival beyond what was previously possible. I would like to thank our patients and investigators for their courage and dedication in completing LUNAR. And, I would like to thank Novocure’s employees for their unrelenting commitment to patients and their perseverance in propelling Novocure to this major milestone.”
“We are excited about the potential of TTFields to address the unmet medical needs of lung cancer patients around the world. In China, lung cancer is the most common cancer type with approximately 700,000 new NSCLC cases diagnosed each year,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are pleased to contribute and be a part of the LUNAR study and this partnership is yet another great example of how collaboration benefits everyone.”
Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.
I penny pumper writing a narrative that's about to get burnt. Fda clearance is huge!!
NVCR microwave device hype will not last and rapidly fading!!
Those who understand how it works know that its application is at best comparable to chemo in terms of effectiveness & the real life experiences of the prescribing doctors & their cancer patients has been increasingly confirming that!!
Why do you think with a bloated $10B market cap, its earnings are non-existence and dropping??
Comparatively speaking, Chemo kills the cancer as well as the normal cells..
And the helmet, based on it claim mode of action of interfering with replication of fast dividing cells, such as cancer cells, inhibit the division of those cells at the site where the microwaves are targeting. Obviously elsewhere in the body, the cancer cells lives happily and keep invading..
Now consider the fact that activated immune system effector cells, such as the T-cells, are also fast dividing. Meaning that the microwaves also inhibit division of the activated immune cells thus, inhibiting the division of the activated immune cells that might have been estimated in some ways. A defeated claim for immune cell activation!!
So the microwaves Inhibit not only cancer cells replication, but also, activated immune cell replication IMO..
And IMO, the lack of interest of the medical community based on the real life experience of their patients as well as their poor quality of their remaining life at massive cost to them are all supportive of that view!!
A new & innovative alternative that stimulate the totality of the naturally occurring immune system from within is urgently needed!!
LOL -- I tried to short this a couple of time. Got my ass kicked.
$NVCR: You said it....... ust hit $185 in PreMarket
WOW.................. whatta MONSTER move.
GO $NVCR
How many shares of NVCR will be sold over the next few weeks by management?
Not that I'm aware of. Over the last five months or so a number of institutional buying has happened.
Why are the insiders selling? Is something going on?
AACR:
387 / 23 - Blood brain barrier (BBB) disruption by tumor treating fields (TTFields) in a human 3D in vitro model https://www.abstractsonline.com/pp8/#!/10517/presentation/12182
1305 / 15 - Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages https://www.abstractsonline.com/pp8/#!/10517/presentation/16885
1801 / 30 - Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability https://www.abstractsonline.com/pp8/#!/10517/presentation/20545
1866 / 11 - Transcriptomics analysis for identification of pathways involved in the response to Tumor Treating Fields (TTFields) https://www.abstractsonline.com/pp8/#!/10517/presentation/16328
2037 / 15 - Spatial omic changes of malignant pleural mesothelioma following treatment using tumor-treating fields https://www.abstractsonline.com/pp8/#!/10517/presentation/12731
2601 / 14 - Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors https://www.abstractsonline.com/pp8/#!/10517/presentation/12967
2659 / 2 - Inhibition of PI3K sensitized cancer cells to Tumor Treating Fields (TTFields) https://www.abstractsonline.com/pp8/#!/10517/presentation/15079
3156 / 7 - Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction https://www.abstractsonline.com/pp8/#!/10517/presentation/14670
3252 / 21 - Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity https://www.abstractsonline.com/pp8/#!/10517/presentation/16105
3447 / 5 - Tumor treating fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord https://www.abstractsonline.com/pp8/#!/10517/presentation/12120
3450 / 8 - Impact of model inaccuracy on dose estimation in TTFields therapy https://www.abstractsonline.com/pp8/#!/10517/presentation/12124
3465 / 23 - Efficacy of concomitant application of Tumor Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro https://www.abstractsonline.com/pp8/#!/10517/presentation/18151
CT234 / 5 - PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma https://www.abstractsonline.com/pp8/#!/10517/presentation/20361
The IDMC has recommended that the PhIII trial in ovarian should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended that the trial continue to a final analysis.
The primary endpoint of INNOVATE-3, which is examining TTFs in combination with paclitaxel for platinum-resistant ovarian, is OS. Secondary endpoints include PFS, ORR, and severity and frequency of AEs.
Insiders keep dumping.
This thing is a pig
Aren't you aware that NVCR is running five pivotal trials (brain mets from NSCLC, NSCLC, rGBM, ovarian and pancreatic) that will readout in the next few years? As for NWBO, I very much doubt we will ever see data from them, or it will be utter bull.
LOL. NWBO is toast and everybody knows it. They are morphing into a CDMO that will be worth a few hundred million.
NVCR will live or die by the lung cancer trial. If that fails they can continue to eak out an existence, but no real upside. If it works, they can say bye-bye to tiny markets like GBM.
NWBO successful trial will crush this stock, yall heard it from me first. I see you Ex, i see you...
NVCR is going to be a trading stock for a while. I do not see any likely positive/negative drivers within the next year.
There is the IA in the ovarian trial in the next month or two. But that is so early that it is 90% to be the blah "trials continues as planned".
I doubt any real excitement on the operation/financial side. Hopefully a bit more uptick than the last set of numbers.
So, play your charts to your hearts content
Getting interesting $NVCR, how far below 200dma will it go? GLTA
Watching $NVCR closely, looking to get back in real soon! GLTA
So what exactly does the news mean?
I have never heard of a DSMB recommending that the trial stop enrollment and add a 12 month follow-up window to keep the same power.
In the proper sense, all keeping the same power means is that they expect the same number of events. If so, this could be no more that NVCR saw that enrollment was so slow they might as well just wait the 12 months than keep trying to enroll.
In the best sense, the DSMB sees the curves separating so well that they know they have sufficient patients and only need time to collect AEs.
In the worst case, the DSMB just called for a futility halt and NVCR is spinning it. In the cases where a futility halt happens before enrollment is complete. the trial can continue but it is unethical to enroll more patients. An that does match what just happened.
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
550
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |